Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination is a nutraceutical formulation designed to leverage the synergistic effects of Mediterranean diet components for cardiovascular and metabolic health. Olive oil polyphenols, primarily hydroxytyrosol and oleuropein, provide potent antioxidant and anti-inflammatory effects, specifically protecting low-density lipoprotein (LDL) particles from oxidative damage. Vitamin D (typically cholecalciferol) acts as a hormone precursor that regulates calcium homeostasis and immune function through the Vitamin D receptor (VDR). Docosahexaenoic acid (DHA) is an omega-3 fatty acid that serves as a structural component of cell membranes and acts as a ligand for peroxisome proliferator-activated receptors (PPARs), which regulate lipid metabolism and inflammatory gene expression. The combination is primarily investigated for its ability to reduce cardiovascular risk factors, improve lipid profiles, and mitigate systemic inflammation in populations with metabolic syndrome or at risk for atherosclerosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olive oil polyphenols + vitamin D + docosahexaenoic acid.